Chimeric Antigen Receptor News and Research

RSS

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

CHOP researchers unlock 3D structure of crucial protein for cancer therapy

Chimeric Antigen Receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.

1 Dec 2023

New approach enhances CAR T-cell therapy for solid tumors

Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent leukemia.

30 Nov 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

Researchers develop $1 cancer treatment using engineered bacteria

What if a single one-dollar dose could cure cancer?

27 Nov 2023

Novel method can detect contaminants in T-cell cultures within 24 hours

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a novel method capable of identifying contaminants in T-cell cultures within 24 hours.

27 Nov 2023

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

Findings from St. Jude Children's Research Hospital are moving the field of cancer immunotherapy one step closer to treating brain and solid tumors.

21 Nov 2023

Scientists uncover key to enhancing cancer-killing T cells

T cells are the key immune system component involved in killing cancer. Tumors produce signals that turn off these T cells, partially by forcing them to progressively differentiate (mature) into a hypofunctional state known as exhaustion.

21 Nov 2023

New approach to CAR T cell therapy may extend treatment effectiveness

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient's T cells so they recognize and attack cancer cells.

14 Nov 2023

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

A prospective path for allogeneic cellular immunotherapies.

13 Nov 2023

Gamma delta T cells engineered to be more potent and long-lasting against cancer

UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.

8 Nov 2023

CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus

New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines.

7 Nov 2023

Overcoming T-cell exhaustion: A new hope for CAR-T cell therapy

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful.

6 Nov 2023

New bioreactor could accelerate access to cancer-killing immunotherapy

A new tool to rapidly grow cancer-killing white blood cells could advance the availability of immunotherapy, a promising therapy which harnesses the power of the body's immune response to target cancer cells.

26 Oct 2023

Researchers discover new way to trigger programmed cell death in cancer cells

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

24 Oct 2023

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

19 Oct 2023

Engineered bacteria deliver synthetic targets to solid tumors

For several years, researchers have been successfully using chimeric antigen receptor (CAR) T cells to target specific antigens found on blood cells as a cure for patients with leukemia and lymphoma.

12 Oct 2023

New nanocapsule treatment boosts immune response against solid tumors

UCLA researchers have developed a new treatment method using a tiny nanocapsule to help boost the immune response, making it easier for the immune system to fight and kill solid tumors.

11 Oct 2023

Chimeric Antigen Receptor News and Research

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

CHOP researchers unlock 3D structure of crucial protein for cancer therapy

New approach enhances CAR T-cell therapy for solid tumors

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Researchers develop $1 cancer treatment using engineered bacteria

Novel method can detect contaminants in T-cell cultures within 24 hours

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

Scientists uncover key to enhancing cancer-killing T cells

New approach to CAR T cell therapy may extend treatment effectiveness

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

Gamma delta T cells engineered to be more potent and long-lasting against cancer

CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus

Overcoming T-cell exhaustion: A new hope for CAR-T cell therapy

New bioreactor could accelerate access to cancer-killing immunotherapy

Researchers discover new way to trigger programmed cell death in cancer cells

CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Engineered bacteria deliver synthetic targets to solid tumors

New nanocapsule treatment boosts immune response against solid tumors

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News